International Journal of Pharmacology 1811-7775 1812-5700 Asian Network for Scientific Information 10.3923/ijp.2018.116.120 1 or A2a Receptors Using Radioligand Binding Assay]]> Kalkan Sule Hocaoglu Nil Buyukdeligoz Mujgan Gurdal Hakan 1 2018 14 1 Background and Objective: Tricyclic antidepressants such as amitriptyline (AMT) may result in life-threatening cardiovascular toxicities. Previous studies showed that AMT-induced cardiovascular toxic effects were prevented/reversed by selective adenosine receptor (AR) antagonists. This study aimed to examine whether AMT mediates its cardiovascular effect through binding to ARs and for this purpose measured the binding affinity of AMT to A1-or A2a-ARs. Materials and Methods: Membranes expressing the A1- or A2a-ARs were labeled with their specific radioactive ligands ([3H]-cyclopentyl-1,3-dipropylxanthine and [3H]CGS21680, respectively). The displacement of the radioligand binding was determined in the presence of different concentrations of AMT or the selective adenosine receptor antagonists for A1-AR and A2a-AR, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) and [8-(3-Chlorostyryl) caffeine (CSC), respectively. The student’s t-test was used to compare the differences of two groups. Results: The bound A2a-AR radioligand was completely displaced by AMT and the Ki value was calculated [half-maximal inhibitory concentration (IC50): 51.42±15.87 μM and Ki: 4.8±0.11 μM, p<0.05]. High concentrations of AMT (10–4 and 10–3 M) inhibited radioligand binding to the A1-AR, which was nearly 25% (p<0.05). Conclusion: AMT showed significant binding to the A2a-AR, which might play an important role in its pharmacological and toxicological effects. Finally, the toxicity of high AMT concentrations may be mediated through the A1-AR.

]]> Mowry, J.B., D.A. Spyker, D.E. Brooks, N. McMillan and J.L. Schauben, 2015 Clin. Toxicol., 53 962 1147 Unverir, P., R. Atilla, O. Karcioglu, H. Topacoglu, Y. Demiral and Y. Tuncok, 2006 Hum. Exp. Toxicol., 25 605 612 Liebelt, E.L., 2006 Cyclic Antidepressants. 2006 pp: 1083-1098 pp: 1083-1098 Castillo-Hernandez, M.C., E. Lara-Padilla, A. Kormanovski-Kovzova, J.G. Perez-Tunon, E.M. Lopez-Calderon and G.G. Balcazar, 2015 Int. J. Pharmacol., 11 508 512 Benowitz, N.L., 2007 Antidepressants, Tricyclic. 2007 pp: 91-93 pp: 91-93 Truven Health Analytics, 2017 In Micromedex. 2017 Lynge, J. and Y. Hellsten, 2000 Acta Physiol. Scand., 169 283 290 Belardinelli, L., J.C. Shryock, S. Snowdy, Y. Zhang and A. Monopoli et al., 1998 2A adenosine receptor mediates coronary vasodilation.]]> J. Pharmacol. Exp. Ther., 284 1066 1073 Kalkan, S., O. Aygoren, A. Akgun, S. Gidener, H. Guven and Y. Tuncok, 2004 J. Toxicol.: Clin. Toxicol., 42 945 954 Kalkan, S., N. Hocaoglu, A. Akgun, S. Gidener and Y. Tuncok, 2007 Clin. Toxicol., 45 600 604 Akgun, A., S. Kalkan, N. Hocaoglu, S. Gidener and Y. Tuncok, 2008 Clin. Toxicol., 46 677 685 Kalkan, S., K. Oransay, I.B. Bal, M. Ertunc, Y. Sara and A.B. Iskıt, 2013 Hum. Exp. Toxicol., 32 62 69 Perkin Elmer, 2009 Human adenosine A1 receptor. 2009 McPherson, G.A., 1983 Comput. Programs Biomed., 17 107 113 Chen, J.F., H.K. Eltzschig and B.B. Fredholm, 2013 Nat. Rev. Drug Discov., 12 265 286 Sheth, S., R. Brito, D. Mukherjea, L.P. Rybak and V. Ramkumar, 2014 Int. J. Mol. Sci., 28 2024 2052 Cronstein, B.N. and M. Sitkovsky, 2017 Nat. Rev. Rheumatol., 13 41 51 Spina, D. and C.P. Page, 2017 Handb. Exp. Pharmacol., 237 63 91 Lerman, B.B. and L. Belardinelli, 1991 Circulation, 83 1499 1509 Shen, W.K. and Y. Kurachi, 1995 Mayo Clin. Proc., 70 274 291 Liu, J., A.R. Reid and J. Sawynok, 2013 Eur. J. Pharmacol., 698 213 219